Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06254261
PHASE2

A Study of RAY1225 in Participants With Obesity

Sponsor: Guangdong Raynovent Biotech Co., Ltd

View on ClinicalTrials.gov

Summary

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Obesity

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

270

Start Date

2024-02-21

Completion Date

2025-12-20

Last Updated

2025-03-19

Healthy Volunteers

No

Conditions

Interventions

DRUG

RAY1225

Administered SC

DRUG

Placebo

Placebo

Locations (1)

Peking University People's Hospital

Beijingcun, Hebei, China